Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b double-blind placebo-controlled study of ARO-APOC3 in adults with severe hypertriglyceridemia
NL-OMON54297Phase 2Recruiting
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Jun 2022
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of plozasiran in hypertriglyceridemia and dyslipidemia (6 arms), sponsored by Arrowhead Pharmaceuticals. Primary endpoint: Percent change from baseline at Week 24 in fasting triglycerides. Started Jun 2022; status: recruiting.
02
Drugs
plozasiran
03
Conditions
hypertriglyceridemiadyslipidemia
Beyond the preview
Go deeper on NL-OMON54297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54297.